CSI Market
Sign In | Register

Puma Biotechnology Inc (PBYI) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access PBYI Annual Cash Flow →
The quarterly cash flow data below helps track how Puma Biotechnology Inc's liquidity profile has evolved over recent quarters.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Mar 31 2026)
3 Months 		(Dec 31 2025) (Sep 30 2025) (Jun 30 2025) (Mar 31 2025)
Operating Activities
Income-3.75
Depreciation & amortization2.58
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Asset Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-3.18
Research and Development in Process0.00
Gain (Loss) on Disposition of Property Plant Equipment0.01
Share-based Compensation1.90
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Extinguishment Of Debt Gain Loss Net Of Tax-
Acquired Inprocess Research And Development-
Increase Decrease In Postmarketing Commitment Liability-0.50
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable27.33
Increase (Decrease) in Accounts Payable3.11
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities-11.69
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expenses, Other0.12
Other Working Capital0.06
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-0.55
Discontinued operations0.00
Net Cash flow from Operating Activities15.42
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Proceeds from Maturities, Prepayments and Calls of Available-for-sale Securities27.34
Payments to Acquire Available-for-sale Securities, Debt-24.86
Real Estate Investments0.00
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire in Process Research and Development0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities2.47
Financing Activities
Short-term debt Net0.00
Other borrowing transactions-0.22
Long-term debt - borrowings-11.11
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Installment Payments To Acquire Intangible Assets-
Payment For Debt Extinguishment Debt Prepayment Cost And Other Extinguishment Costs-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-11.33
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow15.42
Total Cash Flow6.56
4 historic quarters locked

Sign in to unlock the full Puma Biotechnology Inc cash flow history.

Sign In Create Free Account

About Puma Biotechnology Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001437749-26-026311

Figures are derived from filed reports and may be restated. Historical data is subject to revision.